| Title |
Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer
|
|---|---|
| Published in |
Cochrane database of systematic reviews, August 2012
|
| DOI | 10.1002/14651858.cd007814.pub2 |
| Pubmed ID | |
| Authors |
Sanjeev Deva, Michael Jameson |
| Abstract |
Anecdotal reports of tumour regression with histamine type 2 receptor antagonists (H(2)RAs) have lead to a series of trials with this class of drug as adjuvant therapy to try and improve outcomes in patients with resected colorectal cancers. There was a plausible scientific rationale suggesting merit in this strategy. This included improved immune surveillance (by way of increasing tumour infiltrating lymphocytes), inhibiting the direct proliferative effect of histamine as a growth factor for colorectal cancer and, in the case of cimetidine, inhibiting endothelial expression of E-selectin (a cell adhesion molecule thought to be critical for metastatic spread). |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Belgium | 1 | <1% |
| Unknown | 111 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 15% |
| Student > Master | 14 | 13% |
| Student > Ph. D. Student | 12 | 11% |
| Student > Bachelor | 11 | 10% |
| Other | 7 | 6% |
| Other | 11 | 10% |
| Unknown | 40 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 34% |
| Nursing and Health Professions | 11 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Immunology and Microbiology | 3 | 3% |
| Economics, Econometrics and Finance | 2 | 2% |
| Other | 11 | 10% |
| Unknown | 44 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 July 2021.
All research outputs
#4,280,385
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#6,558
of 11,842 outputs
Outputs of similar age
#29,612
of 186,217 outputs
Outputs of similar age from Cochrane database of systematic reviews
#111
of 217 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,217 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 217 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.